vs
礼来（LLY）与RYDER SYSTEM INC（R）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是RYDER SYSTEM INC的1.5倍（$19.3B vs $13.1B），礼来净利率更高（34.4% vs 0.7%，领先33.7%），礼来同比增速更快（42.6% vs 1.0%），过去两年RYDER SYSTEM INC的营收复合增速更高（102.9% vs 48.3%）
礼来（Eli Lilly and Company）是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，1876年由美国内战时期联邦军退伍药剂师伊莱·礼来创立，目前在18个国家设有办事处，产品销往全球约125个国家，是全球知名的制药厂商。
Ryder System Inc.是美国专业运输物流服务商，总部位于佛罗里达州科勒尔盖布尔斯，业务覆盖美国及英国，核心业务包含卡车租赁、车队管理、供应链及运输管理，同时提供车辆维保、二手车销售、专业司机派遣、电商履约与最后一公里配送等多元服务。
LLY vs R — 直观对比
营收规模更大
LLY
是对方的1.5倍
$13.1B
营收增速更快
LLY
高出41.6%
1.0%
净利率更高
LLY
高出33.7%
0.7%
两年增速更快
R
近两年复合增速
48.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.3B | $13.1B |
| 净利润 | $6.6B | $93.0M |
| 毛利率 | 82.5% | — |
| 营业利润率 | 42.8% | — |
| 净利率 | 34.4% | 0.7% |
| 营收同比 | 42.6% | 1.0% |
| 净利润同比 | 50.5% | -5.1% |
| 每股收益（稀释后） | $7.39 | $2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LLYR
| Q1 26 | — | $13.1B | ||
| Q4 25 | $19.3B | $3.2B | ||
| Q3 25 | $17.6B | $3.2B | ||
| Q2 25 | $15.6B | $3.2B | ||
| Q1 25 | $12.7B | $3.1B | ||
| Q4 24 | $13.5B | $3.2B | ||
| Q3 24 | $11.4B | $3.2B | ||
| Q2 24 | $11.3B | $3.2B |
净利润LLYR
| Q1 26 | — | $93.0M | ||
| Q4 25 | $6.6B | $132.0M | ||
| Q3 25 | $5.6B | $138.0M | ||
| Q2 25 | $5.7B | $131.0M | ||
| Q1 25 | $2.8B | $98.0M | ||
| Q4 24 | $4.4B | $135.0M | ||
| Q3 24 | $970.3M | $142.0M | ||
| Q2 24 | $3.0B | $127.0M |
毛利率LLYR
| Q1 26 | — | — | ||
| Q4 25 | 82.5% | — | ||
| Q3 25 | 82.9% | — | ||
| Q2 25 | 84.3% | — | ||
| Q1 25 | 82.5% | — | ||
| Q4 24 | 82.2% | — | ||
| Q3 24 | 81.0% | — | ||
| Q2 24 | 80.8% | — |
营业利润率LLYR
| Q1 26 | — | — | ||
| Q4 25 | 42.8% | 5.6% | ||
| Q3 25 | 41.1% | 6.0% | ||
| Q2 25 | 43.6% | 5.8% | ||
| Q1 25 | 27.2% | 4.3% | ||
| Q4 24 | 37.2% | 5.7% | ||
| Q3 24 | 13.9% | 5.9% | ||
| Q2 24 | 31.1% | 5.6% |
净利率LLYR
| Q1 26 | — | 0.7% | ||
| Q4 25 | 34.4% | 4.2% | ||
| Q3 25 | 31.7% | 4.4% | ||
| Q2 25 | 36.4% | 4.1% | ||
| Q1 25 | 21.7% | 3.1% | ||
| Q4 24 | 32.6% | 4.2% | ||
| Q3 24 | 8.5% | 4.5% | ||
| Q2 24 | 26.3% | 4.0% |
每股收益（稀释后）LLYR
| Q1 26 | — | $2.34 | ||
| Q4 25 | $7.39 | $3.22 | ||
| Q3 25 | $6.21 | $3.32 | ||
| Q2 25 | $6.29 | $3.13 | ||
| Q1 25 | $3.06 | $2.27 | ||
| Q4 24 | $4.88 | $3.09 | ||
| Q3 24 | $1.07 | $3.24 | ||
| Q2 24 | $3.28 | $2.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.3B | $182.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.5B | $2.9B |
| 总资产 | $112.5B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LLYR
| Q1 26 | — | $182.0M | ||
| Q4 25 | $7.3B | $198.0M | ||
| Q3 25 | $9.9B | $189.0M | ||
| Q2 25 | $3.5B | $180.0M | ||
| Q1 25 | $3.2B | $151.0M | ||
| Q4 24 | $3.4B | $154.0M | ||
| Q3 24 | $3.5B | $162.0M | ||
| Q2 24 | $3.4B | $164.0M |
总债务LLYR
| Q1 26 | — | — | ||
| Q4 25 | — | $6.8B | ||
| Q3 25 | — | $7.3B | ||
| Q2 25 | — | $7.0B | ||
| Q1 25 | — | $6.7B | ||
| Q4 24 | $29.5B | $6.7B | ||
| Q3 24 | — | $6.6B | ||
| Q2 24 | — | $6.5B |
股东权益LLYR
| Q1 26 | — | $2.9B | ||
| Q4 25 | $26.5B | $3.1B | ||
| Q3 25 | $23.8B | $3.1B | ||
| Q2 25 | $18.3B | $3.1B | ||
| Q1 25 | $15.8B | $3.0B | ||
| Q4 24 | $14.2B | $3.1B | ||
| Q3 24 | $14.2B | $3.1B | ||
| Q2 24 | $13.6B | $3.1B |
总资产LLYR
| Q1 26 | — | — | ||
| Q4 25 | $112.5B | $16.4B | ||
| Q3 25 | $114.9B | $16.5B | ||
| Q2 25 | $100.9B | $16.5B | ||
| Q1 25 | $89.4B | $16.4B | ||
| Q4 24 | $78.7B | $16.7B | ||
| Q3 24 | $75.6B | $16.5B | ||
| Q2 24 | $71.9B | $16.4B |
负债/权益比LLYR
| Q1 26 | — | — | ||
| Q4 25 | — | 2.24× | ||
| Q3 25 | — | 2.35× | ||
| Q2 25 | — | 2.27× | ||
| Q1 25 | — | 2.21× | ||
| Q4 24 | 2.08× | 2.14× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 2.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2B | $583.0M |
| 自由现金流经营现金流 - 资本支出 | — | $273.0M |
| 自由现金流率自由现金流/营收 | — | 2.1% |
| 资本支出强度资本支出/营收 | — | 3.3% |
| 现金转化率经营现金流/净利润 | 0.49× | 6.27× |
| 过去12个月自由现金流最近4个季度 | — | $595.0M |
8季度趋势，按日历期对齐
经营现金流LLYR
| Q1 26 | — | $583.0M | ||
| Q4 25 | $3.2B | $749.0M | ||
| Q3 25 | $8.8B | $442.0M | ||
| Q2 25 | $3.1B | $752.0M | ||
| Q1 25 | $1.7B | $651.0M | ||
| Q4 24 | $2.5B | $558.0M | ||
| Q3 24 | $3.7B | $629.0M | ||
| Q2 24 | $1.5B | $552.0M |
自由现金流LLYR
| Q1 26 | — | $273.0M | ||
| Q4 25 | — | $344.0M | ||
| Q3 25 | — | $-85.0M | ||
| Q2 25 | — | $63.0M | ||
| Q1 25 | — | $137.0M | ||
| Q4 24 | — | $-201.0M | ||
| Q3 24 | — | $30.0M | ||
| Q2 24 | — | $-87.0M |
自由现金流率LLYR
| Q1 26 | — | 2.1% | ||
| Q4 25 | — | 10.8% | ||
| Q3 25 | — | -2.7% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | -6.3% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | -2.7% |
资本支出强度LLYR
| Q1 26 | — | 3.3% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | — | 16.6% | ||
| Q2 25 | — | 21.6% | ||
| Q1 25 | — | 16.4% | ||
| Q4 24 | — | 23.8% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 20.1% |
现金转化率LLYR
| Q1 26 | — | 6.27× | ||
| Q4 25 | 0.49× | 5.67× | ||
| Q3 25 | 1.58× | 3.20× | ||
| Q2 25 | 0.55× | 5.74× | ||
| Q1 25 | 0.60× | 6.64× | ||
| Q4 24 | 0.56× | 4.13× | ||
| Q3 24 | 3.83× | 4.43× | ||
| Q2 24 | 0.49× | 4.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
R
暂无分部数据
